PKD Connection Blog

In light of our exciting news about JYNARQUE™ (tolvaptan) receiving FDA approval as the first ADPKD treatment, we reached out to Benjamin Cowley Jr., M.D. to explain how we reached this amazing milestone. Dr. Cowley was on the Independent Data […]

Our Chief Scientific Officer David Baron, Ph.D. recently attended American Society of Nephrology’s Kidney Week 2017. The annual meeting brings together 13,000 kidney professionals across the globe, providing opportunities to exchange knowledge, learn about the latest scientific and medical advances, and […]

An investigational drug being developed for the treatment of autosomal dominant polycystic kidney disease (ADPKD) has received orphan drug designation by the U.S. Food and Drug Administration (FDA). Lixivaptan is a potent, selective vasopressin V2 receptor antagonist which may delay […]